Hello and good afternoon, everyone. This is Stuart Gander here, CEO of Q-linea AB. I'm joined by my CFO Christophe Samuelson for this Q2 report. So thank you for taking the time to join us. Um, we'll do this similar to previous webcasts; I will make some opening comments to give you a general sense of where we are in the business.
Um, some of the highlights from the last quarter include, Uh, and then I'll turn it over to Christophe, Who will walk us through the financials for the quarter. So with that, just a quick flash of our regular disclaimer here. So you've read that with respect to any forward-looking statements.
Um, a few of the key messages I wanted to make sure that you hear during our discussion today include, Number one, following the FDA approval at the end of April, we're now in full commercial push mode in the US. Um, I'll speak to it more in detail, but obviously, this is a very large market, with a significant opportunity for rapid growth. So we're being very thoughtful in terms of how we approach and segment it. So we utilize our relatively small commercial team on the ground where we have the most opportunity for early-stage traction.
So I'll talk a little bit about that second piece related to our commercial expansion on the geographic side. We've had a presence now in Western Europe for some time. And with the expansion into the US, our focus is now shifting to a global and steady expansion of the ASTar opportunity around the world. Um, obviously, there are a great number of geographies and potential partners. So, we're being thoughtful in terms of how we deploy resources and which markets we enter at what time, so that we don't get too far over our skis, but at the same time open up new opportunities for ASTar to reach patients.
Thirdly, we've talked about this before, but the cost-saving program that was initiated at the beginning of this year has been completed. Christophe will speak more to the details, but all of those changes have been done as planned and on time. And in fact, on the cost side, we're slightly above the cost reduction projection that we anticipated or, to be precise, slightly more savings than we anticipated. So we will see those coming through the back end of this year and then finally, again, as communicated previously, we're very pleased that we've had an extended financing arrangement with Nexttobe, our largest shareholder. And that will carry us through into the back part of this year.
So those are some of the key messages and with that I'll get into the next level of detail here. As for areas of focus for me since joining and stepping into the role roughly four months ago, Number one, that commercial acceleration is paramount. So we have now shipped our first instruments to the US with dedicated US software and specifications. And with the FDA approval, we now have a US-approved menu. The instruments that are now being installed can remain on-site once customers sign the contract. Previously, customers had the opportunity to use the ASTar platform under early access programs and for clinical work. But now, these are commercial instruments being sent to the US for evaluations. A key point here is our ongoing reception of support from CMS regarding NTAP reimbursement funding. We have not yet received final approval from CMS, but they have recommended reimbursement coverage at $97.50 per patient. So, this would be applicable for any Medicare patients undergoing a rapid AST test on the ASTar platform. This will help laboratories and hospitals offset the costs of rapid AST tests. We expect this will not only accelerate the adoption of rapid AST but will also promote the consideration of ASTar by hospitals and laboratories.
Commercial traction in our other core markets has also continued. We have shipped an additional unit to Italy. We announced another tender that we are participating in in Belgium. Several other markets are showing progress in terms of customers evaluating and contracting our ASTar platform. We hope to share more updates on these developments soon. As I mentioned previously, we are thoughtfully considering our geographic expansion and customer engagement on both the scientific and commercial fronts. I also noted in last quarter's report our presentations at ASM, which were very well received. We have interim results from our health economics and outcomes research study in Italy.
We shared highlights of these results at the ASM conference in the US, which continued to generate strong interest from customers, and it's encouraging to see the broader industry invest in publications on the benefits of rapid AST. This has become a prominent topic with an increasing body of evidence supporting the practical and clinical advantages of rapid AST for hospitals. My second area of focus, following customer acceleration, has been on innovation and product development. The recent FDA approval marks a culmination of significant effort by our team to secure access to the US market.
Our work doesn't stop there. We have submitted the second version of our menu, which will provide additional drug-bug combinations to our US customers, further enhancing our offering. Throughout this period of restructuring, which posed significant demands on the organization, we have successfully met all internal development milestones. This underscores the commitment and capabilities of our development team. We continue to expand the capabilities of ASTar with next-generation software and additional menu options.
The third focus area for me has been organizational development. Having completed the restructuring process, we are now settling into the new organizational structure moving forward. We are making targeted investments, including in the US market, where we have added team members to enhance our commercial launch, significantly boosting our presence in that market.
We are also focusing on strengthening the end-to-end customer care and service support experience. We anticipate deploying a number of our instruments globally in the near future. And this will place more demands on the service team. So this is one of the key areas of, uh, focus for the team in the months ahead. And then finally, on the financial side, um, overall tracking ahead of the budget that was set. Uh, we see those costs coming down slightly faster than anticipated, which is good news. Krista will speak to that more in detail.
Um, you know, my focus and that of the team, really, uh, remains on driving the top line growth. Uh, keeping in mind that in many of the markets, we will expect to see reagent rental models, which means when instruments go out, it does take a little bit of time for the revenues to come in as usage of those. uh, you know, grows over time and, and, and customers buy and use kits for their patients. So with that, um, maybe I'll just jump into some further comments. Um, for those that are new to rapid AST, um, you know, it's worth reiterating our core proposition, which is, in our view, a market-leading one.
The platform promises a less than six hour turnaround time for critical blood infections. Um, uh, diagnosis, uh, which both in terms of clinical impact has a clear benefit in reducing the impact of sepsis and saving lives. It also saves time and money, and critically lab time. And in managing the patient workflow. Um, the actual workflow on the instrument is second to none.
It's less than two minutes of hands-on time. Very simple interface and critically is a continuous access and random access platform with very minimal training needed for a user, making it very easy to plug into any microbiology lab around the world. Um, and then finally, with respect to that menu, very comprehensive menu. Um, and continues to demonstrate very strong performance in the field with respect to consistency, reproducibility of test results. So here's a quick view of our US-cleared ASTar panel.
Uh, we received that clearance on April 26th, so we're very proud of that. Um, this panel will continue to be strengthened. As I mentioned earlier, with a version two, um, we will leverage the clinical data that's been gathered over the next few months for that resubmission. Um, and we will expect to see that, uh, in the quarters ahead. So with respect to the US market, um, you know, as I mentioned, there's, uh, it's a very special and big market, uh, geographically large and relatively complex in terms of the makeup of different types of hospitals, labs, configurations, etc..
So, uh, the first order of business for us is to be very thoughtful and structured. Uh, the team has done a great job segmenting the roughly 1600 or so labs that we think are relevant for the platform, and really focusing on the top 50 to around 100 of those centers. These are the labs, both that have the volumes, um, that, that make it very interesting to start there. But also crucially, are ones that have proven themselves to be early adopters of technologies. They often have key opinion leaders and thought leaders in the field. The types of decision makers that can move quickly with their lab to bring new and beneficial technologies to their patients. We are actively engaging with several dozen of these and are now setting up evaluations over the coming months. So, we'll expect to see the contracting periods for those comments after the evaluations. The main thing here for us is to really demonstrate the performance of ASTar by getting the instrument into the hands of lab techs and lab managers who use it day to day. And we see consistently very strong feedback once the instrument is in the lab, that folks see the benefits and the usability advantages of the ASTar approach. We believe this will lead to a very strong reception, based on the evaluations that we're now setting up. Attention will eventually shift from initiating evaluations to the conversion in contracting over the coming months. In support of that customer engagement, I had the privilege of joining the team in Atlanta in June for the ASM conference, which is the largest US-based microbiology conference. It sort of mirrors in some ways the earlier estimated conference. We were obviously able to leverage some of those similar scientific findings for our poster presentations. And it gives us an opportunity to interact with more than 5000 clinicians and scientists in the field across the US. It was interesting to note that, as with ECCMID, rapid AST remains a focus area for research and scientific endeavor in the field. We're also not the only players discussing this space. As I mentioned, there are a number of studies and poster presentations coming out that really further support the clinical benefits of rapid AST. Um, so speaking to that, it's worth highlighting again, the interim results from our health economics and outcomes research in Italy. We've discussed this previously, but the numbers are worth highlighting again, as we see up to 34 hours of improvement in time to result when using ASTar versus the current standard of care in the sepsis environment, where every hour counts and every hour leads to increased mortality. This has tremendous benefits for the outcome of the patient. We've noted in the interim results that nearly half, just under half of patients had an adjustment in therapy. That means that these patients are either receiving, in many cases, an escalation in therapy that would suggest that their clinical outcomes may have been worse had they not received a different, inappropriate therapy. Crucially, improved stewardship and retaining the ability to use our most impactful drugs for patients truly when it matters. Rather than addressing the antimicrobial resistance challenge. So, this is just some of the data that's coming out into the market and encouraging the shift towards rapid AST. So just to round off a little bit here, um, you know, we continue to focus very much in the immediate phase here on the commercializatioon of the ASTar platform. In Europe, in the US, and now increasingly globally, our development pipeline is focused on further strengthening the proposition of the ASTar. Uh, with menu expansion. We've mentioned, for example, Gram-positive, which is another roughly 50% of the patients with bloodstream infections. We would expect to expand that menu in the future. Additionally, down the road, there are further applications pertaining to other test types and modalities moving forward. So with that, I'll turn over the comments to Kristen to highlight the financial developments for the quarter.